B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
about
The Role of Peripheral CNS-Directed Antibodies in Promoting Inflammatory CNS Demyelination.A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.In Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis.No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a."B cells and autoimmunity 2016".Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trialA tyrosine sulfation-dependent HLA-I modification identifies memory B cells and plasma cells
P2860
Q38714054-FB410B12-119A-4DEF-A2DA-822545BDE966Q39458392-64CE9260-D59F-4CC4-9B3D-9305F2630E0DQ42371905-F8963761-92C2-4AAB-910E-CCAC5847B5A5Q52641471-42620A12-9D1B-4349-88CF-305F4211ABBEQ53802747-5C37CF30-2748-4A02-82CC-D57AD21C15E1Q58697770-5023B822-7597-48D6-9BD4-4E9CD6DBA36FQ58699743-C47CE453-1683-4555-91ED-89F715E41EA5
P2860
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
@en
type
label
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
@en
prefLabel
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
@en
P2860
P1433
P1476
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
@en
P2093
Martin S Weber
Silke Kinzel
P2860
P2888
P304
P356
10.1007/S40263-016-0396-6
P577
2016-11-14T00:00:00Z